Home › Ovarian Epithelial Carcinoma › Massachusetts
Ovarian Epithelial Carcinoma clinical trials in Massachusetts
9 studies for Ovarian Epithelial Carcinoma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
A Study of Isoquercetin in People With Ovarian Cancer
- Beth Israel Deaconess Medical Center (Data Collection Only), Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07303894AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Burlington
- Research Site, Worcester
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 21, 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 2, 2026 · NCT06819007A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- Site 0104, Boston
RecruitingPhase 1
Ages 18 and older · Women · Updated Apr 7, 2026 · NCT04516447A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 27, 2026 · NCT06395519A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · Women · Updated Feb 3, 2026 · NCT06469281CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Massachusetts General Hospital, Boston
RecruitingPhase 2
Ages 18 and older · Women · Updated Dec 23, 2025 · NCT06690775Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
- Massachusetts General Hospital, Boston
RecruitingObservational study
Ages 30 and older · Women · Updated Sep 16, 2025 · NCT04794322Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Dana Farber/Partners Cancer Care Inc, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 15, 2025 · NCT04429542From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.